ATAI | LIFE SCIENCES
310
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-310,,qode-page-loading-effect-enabled,qode-title-hidden,qode_grid_1400,qode-child-theme-ver-1.0.0,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.6,vc_responsive

The biotech platform to ultimately cure mental health disorders.

About us

Leveraging cutting-edge
scientific research and technology

Who we are

ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering with mental health disorders.

 

Our mission

We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.

 

Our approach

By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based therapies.

Latest from the #InsightNetwork
Our Team

Vast experience
and great access to deal flow

Christian Angermayer

Founder

Florian Brand

Co-Founder and Chief Executive Officer

Matthias Luz

Chief Medical Officer

Srinivas Rao

Chief Scientific Officer

Greg Bates

Lead, Regulatory Affairs

Danny Talati

Lead, Business Development

Aaron Weaver

Senior Legal Counsel

Simon Seibold

Associate

Ana Zarzosa

Team and Research Assistant

Philipp Schreiber

Associate

Allan Malievsky

Associate

Ali Mahomed

Analyst

Our Companies

A portfolio of innovation
Accelerating progress in life sciences

COMPASS Pathways

develops psilocybin therapy for patients with treatment-resistant depression.
compasspathways.com

Perception Neuroscience

develops arketamine therapy for patients with neuropsychiatric diseases.
perceptionneuroscience.com

Innoplexus

leverages the power of AI and big data analytics for a variety of applications in life sciences, like drug development.
innoplexus.com

COMPASS Pathways

develops psilocybin therapy for patients with treatment-resistant depression.
compasspathways.com

Perception Neuroscience

develops arketamine therapy for patients with neuropsychiatric diseases.
perceptionneuroscience.com

Innoplexus

leverages the power of AI and big data analytics for a variety of applications in life sciences, like drug development.
innoplexus.com

Juvenescence

invests in companies with therapies for aging and age-related diseases.
juvenescence.ltd

Insights

Learn about cutting-edge science
and gain life-enhancing insights

Follow us on Twitter and read our blog

Careers

Work with us
to improve the lives of millions of people

WE ARE HIRING! Learn about career opportunities at ATAI and see open jobs across our platform companies.

Join the ATAI #InsightNetwork

Sign up below to receive the latest news on ATAI and innovations in the biotech and mental healthcare space

75%

A biography (or simply bio) is a detailed description of a person’s life. It involves more than just the basic facts like education, work, relationships.

43%

A biography (or simply bio) is a detailed description of a person’s life. It involves more than just the basic facts like education, work, relationships.

87%

A biography (or simply bio) is a detailed description of a person’s life. It involves more than just the basic facts like education, work, relationships.

Christian Angermayer

Founder

Strategy and investor relations

Lars Wilde

Co-Founder

Advising on drug discovery and compound sourcing

The Eight Most Significant Factors Contributing to Today’s Depression Epidemic (sources)

  1. https://www.who.int/news-room/fact-sheets/detail/depression
  2. https://www.ncbi.nlm.nih.gov/pubmed/28027366
  3. https://www.who.int/mental_health/in_the_workplace
  4. https://ada.com/signs-of-depression
  5. https://www.nimh.nih.gov/health/statistics/suicide.shtml
  6. https://adaa.org/about-adaa/press-room/facts-statistics
  7. https://www.nimh.nih.gov/health/statistics/major-depression.shtml
  8. https://www.bcbs.com/the-health-of-america/reports/major-depression-the-impact-overall-health
  9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579396
  10. https://www.ncbi.nlm.nih.gov/pubmed/26651008
  11. https://www.ncbi.nlm.nih.gov/pubmed/15271581
  12. https://www.ncbi.nlm.nih.gov/pubmed/24269030
  13. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889685
  14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006295
  15. https://www.ncbi.nlm.nih.gov/pubmed/11691695
  16. https://www.ncbi.nlm.nih.gov/pubmed/10431682
  17. https://www.ncbi.nlm.nih.gov/pubmed/19434623
  18. https://pediatrics.aappublications.org/content/138/6/e20161878
  19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738337
  20. https://www.cdc.gov/drugoverdose/data/statedeaths.html
  21. http://www.annfammed.org/content/14/1/54
  22. https://www.drugabuse.gov/publications/drugfacts/prescription-opioids
  23. https://www.psychiatrictimes.com/special-reports/opioid-use-elderly
  24. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2682878
  25. https://jamanetwork.com/journals/jama/fullarticle/2684607
  26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841310
  27. https://psycnet.apa.org/record/2008-07755-000
  28. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021390
  29. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225959
  30. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775138
  31. https://jech.bmj.com/content/68/2/110.abstract
  32. https://www.nimh.nih.gov/health/publications/chronic-illness-mental-health/index.shtml
  33. https://adaa.org/serious-chronic-or-terminal-illnesses
  34. https://www.ncbi.nlm.nih.gov/pubmed/30844397
  35. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308579/
  36. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017546/
  37. http://www.pointinstitute.org/wp-content/uploads/2012/10/standard_v_9.2_hpa_axis.pdf
  38. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3860380/
  39. https://www.sciencedirect.com/science/article/pii/S0747563216302552?via%3Dihub
  40. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633215/

Florian Brand

Co-Founder and Chief Executive Officer

Executing drug development and operations

Simon Seibold

Associate

Investments and business development

Philipp Schreiber

Associate

Drug discovery and compound sourcing

ATAI is supporting the revival of treatments with prior evidence in humans, such as psilocybin and ketamine, in fighting mental health disorders

Depression, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, bipolar disorder and other psychiatric conditions are increasingly becoming a burden for patients, families and societies.

We believe that

ATAI is leveraging the potential of artificial intelligence (AI) and big data analytics to optimize and accelerate the drug development process

Technological innovation will enable us to consolidate and make sense of vast amounts of previously inaccessible data.

We believe that

Matthias Luz, MD

Chief Medical Officer

Developing clinical strategy for lead compounds

Srinivas Rao, MD, PhD

Chief Scientific Officer

Advance the science into clinical evaluation

Danny Talati

Lead, Business Development

Compound sourcing and evaluating

Allan Malievsky

Associate

Communications and Business Development

Greg Bates

Lead, Regulatory Affairs

Successful product approval

Aaron Weaver

Senior Legal Counsel

Ana Zarzosa

Team and Research Assistant

Supporting smooth communication and a high-performance team environment

Ali Mahomed

Global Venture Development

Operationally growing portfolio companies

Sources: The Eight Most Significant Factors Contributing to Today’s Depression Epidemic (full series)

  1. https://www.who.int/news-room/fact-sheets/detail/depression
  2. https://www.ncbi.nlm.nih.gov/pubmed/28027366
  3. https://www.who.int/mental_health/in_the_workplace
  4. https://ada.com/signs-of-depression
  5. https://www.nimh.nih.gov/health/statistics/suicide.shtml
  6. https://adaa.org/about-adaa/press-room/facts-statistics
  7. https://www.nimh.nih.gov/health/statistics/major-depression.shtml
  8. https://www.bcbs.com/the-health-of-america/reports/major-depression-the-impact-overall-health
  9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579396
  10. https://www.ncbi.nlm.nih.gov/pubmed/26651008
  11. https://www.ncbi.nlm.nih.gov/pubmed/15271581
  12. https://www.ncbi.nlm.nih.gov/pubmed/24269030
  13. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889685
  14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006295
  15. https://www.ncbi.nlm.nih.gov/pubmed/11691695
  16. https://www.ncbi.nlm.nih.gov/pubmed/10431682
  17. https://www.ncbi.nlm.nih.gov/pubmed/19434623
  18. https://pediatrics.aappublications.org/content/138/6/e20161878
  19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738337
  20. https://www.cdc.gov/drugoverdose/data/statedeaths.html
  21. http://www.annfammed.org/content/14/1/54
  22. https://www.drugabuse.gov/publications/drugfacts/prescription-opioids
  23. https://www.psychiatrictimes.com/special-reports/opioid-use-elderly
  24. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2682878
  25. https://jamanetwork.com/journals/jama/fullarticle/2684607
  26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841310
  27. https://psycnet.apa.org/record/2008-07755-000
  28. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021390
  29. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225959
  30. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775138
  31. https://jech.bmj.com/content/68/2/110.abstract
  32. https://www.nimh.nih.gov/health/publications/chronic-illness-mental-health/index.shtml
  33. https://adaa.org/serious-chronic-or-terminal-illnesses
  34. https://www.ncbi.nlm.nih.gov/pubmed/30844397
  35. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308579/
  36. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017546/
  37. http://www.pointinstitute.org/wp-content/uploads/2012/10/standard_v_9.2_hpa_axis.pdf
  38. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3860380/
  39. https://www.sciencedirect.com/science/article/pii/S0747563216302552?via%3Dihub
  40. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633215/

Ali Mahomed

Global Venture Development Junior Associate

Operationally growing portfolio companies